Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes. It belongs to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors and is taken by mouth. The most common side effects reported for it are genital yeast infections, urinary tract infections and increased urination. The drug was approved for medical use in the United States in January 2023. This entry records what the encyclopedia lead states and is a record of what is held about the drug, not medical advice.
Facts
Classification
Approval Status ATC ClassA: Alimentary Tract and Metabolism 2 Route of Administration First Approved / Isolated Year Prescription Status Mechanism of Action Connections
Long-Form Articles
Treats
Source Bexagliflozin (Wikipedia)
Sources
1. Bexagliflozin (Wikipedia)
Lead paragraph
Bexagliflozin was approved for medical use in the United States in January 2023.
Lead paragraph [route-of-administration]
It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth.
Treats: Type 2 Diabetes, Lead paragraph [treats]
used to improve glycemic control in adults with type 2 diabetes
View the Source2. RxNav RxClass, National Library of Medicine: RxClass ATC classes of Bexagliflozin
RxNav RxClass, National Library of MedicineRxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code A10BK (main group A)Quote, RxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code A10BK (main group A)
"classId": "A10BK", "className": "Sodium-glucose co-transporter 2 (SGLT2) inhibitors", "classType": "ATC1-4"
3. U.S. Food and Drug Administration (openFDA): openFDA drug labels of Bexagliflozin by product type
U.S. Food and Drug Administration (openFDA)count by product typeQuote, count by product type
"term": "HUMAN PRESCRIPTION DRUG", "count": 3
4. ChEMBL: ChEMBL mechanism of action for Bexagliflozin (CHEMBL1808388)
ChEMBLmechanism_of_actionQuote, mechanism_of_action
Sodium/glucose cotransporter 2 inhibitor
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.